Cross-Sector entity
Donald Trump is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. Across a 28-day span, the pace is roughly 1 story per week. The busiest single day carried 3. Coverage clusters in disruptions, which accounts for 1 of those 4, with the remainder spread across 3 other categories.
4 verified stories tracked
Last mentioned: Sep 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Donald Trump is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. Across a 28-day span, the pace is roughly 1 story per week. The busiest single day carried 3. Coverage clusters in disruptions, which accounts for 1 of those 4, with the remainder spread across 3 other categories. This profile follows 4 Cross-Sector stories mentioning Johns Hopkins Bloomberg School of Public Health across the period from August 13, 2026 to September 9, 2026. The tracked stories average 2 original sources each.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johns Hopkins Bloomberg School of Public Health. Shared-story counts are live from our verified record — not editorial picks.
Experts assess the 2026–27 flu season outlook
NBC stations publish expert outlook citing CDC data and Australia's moderate 2026 season as early signals for the U.S.
Scientists update 2026–27 flu vaccines for subclade K strain
Vaccine composition is updated earlier in 2026 to protect against the subclade K influenza strain.
Australia records busiest, deadliest flu season in decades
Australia's 2025 Southern Hemisphere flu season becomes the country's busiest and deadliest in decades, later used as the comparison baseline for 2026.
After the 2025–26 season set a 25-year record for flu-like illness visits, health system leaders are parsing early signals — Australia's moderate 2026 season and the subclade K vaccine update — to gauge 2026–27 capacity, surveillance and forecasting needs.
Source: nbcsandiego.com · nbcbayarea.com
Trump's order to split the MMR vaccine into individual shots threatens to reverse decades of pediatric vaccine bundling, forcing manufacturers and distributors to source millions more syringes, vials, and cold-chain shipments. Procurement teams and clinics face uncertain demand forecasts and rising consumables costs.
Clinicians and public health officials warn the executive order to split the MMR vaccine and space out injections could reduce childhood immunization completion. Pediatric practices face more visits, more documentation, and higher costs with no clinical benefit identified.
Biopharma executives face a potential forced revival of discontinued single-antigen measles, mumps, and rubella vaccines, requiring new manufacturing lines and regulatory work. Analysts estimate tens of millions in upfront costs and years of development before any unbundled schedule could be supplied.
Source: troyrecord.com · greeleytribune.com
